Evidence map›Paper›PMID 30323584›Full record

ArticleInternational journal of nanomedicine2018

A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.

Yanping Lu, Shunping Han, Hongyue Zheng, Rui Ma, Yuting Ping, Jiafeng Zou, Hongxia Tang, Yongping Zhang, Xiuling Xu, Fanzhu Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Nanoscale Drug Delivery Systems in Glioblastoma.Nanoscale research letters · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yanping LuCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Shunping HanCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Hongyue ZhengCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Rui MaCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Yuting PingCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Jiafeng ZouCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Hongxia TangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Yongping ZhangCollege of Pharmaceutical Sciences, Guiyang University of Chinese Medicine, Guiyang, Guizhou, China.
Xiuling XuCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Fanzhu LiCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, xuxiuling@zcmu.edu.cn; lifanzhu@zcmu.edu.cn.
Zhejiang Chinese Medical University · CNGuiyang College of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Traditional Chinese Medicine, arsenic trioxide (ATO, As PURPOSE: The objective of this study was encapsulating ATO in the modified PAMAM den-drimers to solve the problem that the poor antitumor effect of ATO to glioma, which provide a novel angle for the study of glioma treatment.

methodsThe targeting drug carrier (RGDyC-mPEG-PAMAM) was synthesized based on Arg-Gly-Asp (RGDyC) and αvβ3 integrin targeting ligand, and conjugated to PEGylated fifth generation polyamidoamine dendrimer (mPEG-PAMAM). It was characterized by nuclear magnetic resonance, fourier transform infrared spectra, Nano-particle size-zeta potential analyzer,etc. The in vitro release characteristics were studied by dialysis bag method. MTT assay was used to investigate the cytotoxicity of carriers and the antitumor effect of ATO formulation. In vitro blood-brain barrier (BBB) and C6 cell co-culture models were established to investigate the inhibitory effect of different ATO formulation after transporting across BBB. Pharmacokinetic and antitumor efficacy studies were investigated in an orthotopic murine model of C6 glioma.

resultsThe prepared RGDyC-mPEG-PAMAM was characterized for spherical dendrites, comparable size (21.60±6.81 nm), and zeta potential (5.36±0.22 mV). In vitro release showed that more ATO was released from RGDyC-mPEG-PAMAM/ATO (79.5%) at pH 5.5 than that of pH 7.4, during 48 hours. The cytotoxicity of PEG-modified carriers was lower than that of the naked PAMAM on both human brain microvascular endothelial cells and C6 cells. In in vitro BBB model, modification of RGDyC heightened the cytotoxicity of ATO loaded on PAMAM, due to an increased uptake by C6 cells. The results of cell cycle and apoptosis analysis revealed that RGDyC-mPEG-PAMAM/ATO arrested the cell cycle in G2-M and exhibited threefold increase in percentage of apoptosis to that in the PEG-PAMAM/ATO group. Compared with ATO-sol group, both RGDyC-mPEG-PAMAM/ATO and mPEG-PAMAM/ATO groups prolonged the half-life time, increased area under the curve, and improved antitumor effect, significantly. While the tumor volume inhibitory of RGDyC-mPEG-PAMAM/ATO was 61.46±12.26%, it was approximately fourfold higher than the ATO-sol group, and twofold to the mPEG-PAMAM/ATO group.

conclusionIn this report, RGDyC-mPEG-PAMAM could enhance the antitumor of ATO to glioma, it provides a desirable strategy for targeted therapy of glioma.

Indexed as

Drug Delivery SystemsAnimalsApoptosisArsenicalsArsenic TrioxideBlood-Brain BarrierCell CycleCell Line, TumorDendrimersDrug CarriersDrug LiberationEndocytosisGliomaHumansMaleMicearginyl-glycyl-aspartic acidArsenicalsArsenic TrioxideDendrimersDrug Carriersmonomethoxypolyethylene glycolOligopeptidesOxidesPEG-PAMAMPolyethylene Glycolsarsenic trioxideblood-brain barrierglioma targeting deliveryPAMAM dendrimerPEG co-modifiedRGDyC

Identifiers

PMID30323584
PMCPMC6173183
OpenAlexW2893437090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.